Literature DB >> 16600352

A meta-analysis of the performance characteristics of the free prostate-specific antigen test.

Richard Lee1, A Russell Localio, Katrina Armstrong, S Bruce Malkowicz, J Sanford Schwartz.   

Abstract

OBJECTIVES: To conduct a meta-analysis of the diagnostic performance of the percent free prostate-specific antigen (%fPSA) test in determining prostate cancer status and to assess its value in helping to decide whether to biopsy the prostate.
METHODS: Articles identified through a MEDLINE search were included if they presented adequate original primary data to calculate a receiver operating characteristic (ROC) curve in subjects possessing histopathologically verified diagnoses. Articles containing subjects with concurrent, non-prostate-related genitourinary conditions were excluded. Percent free PSA sensitivity, specificity, ROC curves, and positive likelihood ratios were calculated for all PSA ranges and for the reflex range of PSA between 4 and 10 ng/mL.
RESULTS: Among the 41 studies, containing 19,643 subjects, area under the curve for %fPSA was 0.70 for all PSA levels, decreasing to 0.68 in the reflex range. A test cutoff of 20% would lead to 92% sensitivity and 23% specificity. Positive likelihood ratios ranged from 1.0 to 4.0, exceeding 2.0 at %fPSA of 15% or less. Within the reflex range, however, likelihood ratios exceeded 2.0 only at %fPSA of 7% or less.
CONCLUSIONS: Percent free PSA can be a useful adjunct to PSA for primary prostate cancer screening only under certain defined situations. In the "gray zone," or reflex range, of PSA testing, %fPSA improves clinical information only when levels reach extreme values.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16600352     DOI: 10.1016/j.urology.2005.10.052

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  30 in total

1.  Variability of assay methods for total and free PSA after WHO standardization.

Authors:  L Foj; X Filella; J Alcover; J M Augé; J M Escudero; R Molina
Journal:  Tumour Biol       Date:  2013-10-04

2.  Percent free prostate-specific antigen does not improve the effectiveness of prostate cancer detection in Chinese men with a prostate-specific antigen of 2.5-20.0 ng/ml: a multicenter study.

Authors:  Maping Huang; Yurong Lin; Abai Xu; Matthew Uhlman; Xiangrong Deng; Xuanting Lin; Sifeng Wu; Pengfei Diao; Keji Xie; Ping Tang
Journal:  Med Oncol       Date:  2014-03-23       Impact factor: 3.064

3.  The value of an artificial neural network in the decision-making for prostate biopsies.

Authors:  R P Meijer; E F A Gemen; I E W van Onna; J C van der Linden; H P Beerlage; G C M Kusters
Journal:  World J Urol       Date:  2009-06-28       Impact factor: 4.226

4.  Recommandations de l'Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.

Authors:  Ricardo A Rendon; Ross J Mason; Karim Marzouk; Antonio Finelli; Fred Saad; Alan So; Phillipe Violette; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862

5.  Overdiagnosis of prostate cancer.

Authors:  Gurdarshan S Sandhu; Gerald L Andriole
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

6.  Assays for prostate cancer : changing the screening paradigm?

Authors:  Jens Hansen; Michael Rink; Markus Graefen; Shahrokh Shariat; Felix K-H Chun
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

Review 7.  Emerging PSA-based tests to improve screening.

Authors:  Richard J Bryant; Hans Lilja
Journal:  Urol Clin North Am       Date:  2014-02-26       Impact factor: 2.241

Review 8.  Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.

Authors:  George Botchorishvili; Mika P Matikainen; Hans Lilja
Journal:  Curr Opin Urol       Date:  2009-05       Impact factor: 2.309

Review 9.  Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.

Authors:  Stacy Loeb; Hans Lilja; Andrew Vickers
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

10.  A Review on the Clinical Utility of PSA in Cancer Prostate.

Authors:  Mohan Adhyam; Anish Kumar Gupta
Journal:  Indian J Surg Oncol       Date:  2012-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.